Oleic Acid vs Linoleic Acid in Pancreatic Cancer: Divergent Lipid Signaling from SREBP1-SCD1 to Ferroptosis
Oleic acid drives PDAC stemness and ferroptosis resistance via SCD1. Linoleic acid induces ferroptosis through lipid peroxidation and RIP3/MLKL necroptosis.
Molecular Pathway Insights
Oleic Acid vs Linoleic Acid in Pancreatic Cancer: Divergent Lipid Signaling from SREBP1-SCD1 to Ferroptosis
Pancreatic ductal adenocarcinoma rewires lipid metabolism to sustain aggressive growth, chemoresistance, and cancer stem cell self-renewal. Oleic acid (a monounsaturated fatty acid produced by SCD1) and linoleic acid (an omega-6 polyunsaturated fatty acid) exert opposing effects on tumour cell fate: oleic acid drives ferroptosis resistance and stemness through SREBP1-SCD1, while linoleic acid induces iron-dependent lipid peroxidation and RIP3/MLKL-mediated necroptosis. This pathway analysis traces their divergent molecular cascades through PI3K-AKT signaling, mechanosensory regulation, and cell death programming.
Pathogenic origin of lipid-driven PDAC progression
Pancreatic ductal adenocarcinoma progression is driven by the convergence of three metabolic forces: SREBP1-SCD1-dependent lipid biosynthesis that shifts the intracellular fatty acid pool toward monounsaturated species, mechanosensory activation of PI3K-AKT through Piezo1-mediated calcium influx in the stiff desmoplastic stroma, and mitochondrial fatty acid oxidation (FAO) that sustains cancer stem cell bioenergetics under nutrient-deprived and acidic microenvironment conditions (PMID: 40741620; PMID: 39198858; PMID: 32081432). The structural divergence between oleic acid (C18:1, monounsaturated) and linoleic acid (C18:2, polyunsaturated) determines whether the tumour cell acquires ferroptosis resistance or becomes vulnerable to iron-dependent lipid peroxidation. This fatty acid dichotomy, modulated by diet, stromal mechanics, and tumour cell autonomy, defines the metabolic origin of PDAC chemoresistance and cell death evasion.
Molecular mechanism of oleic acid and linoleic acid divergence in PDAC signaling
The oleic acid programme begins with the activation of the SREBP1-SCD1 lipogenic axis. Under nutrient deprivation, PDAC cells upregulate SREBP1 (sterol regulatory element-binding protein 1), which transcriptionally activates SCD1 (stearoyl-CoA desaturase 1), the enzyme that introduces a cis-double bond at the delta-9 position of stearic acid to produce oleic acid (PMID: 41049011). This process is amplified by mechanical cues: stiff extracellular matrix activates the mechanosensitive ion channel Piezo1, triggering Ca2+ influx that feeds into PI3K-AKT signaling and upregulates SCD1 expression (PMID: 40741620). In parallel, PDGFC (platelet-derived growth factor C) activates PI3K-AKT to upregulate SREBP1, promoting fatty acid accumulation and driving liver metastasis (PMID: 39225567). The net effect is an elevated intracellular MUFA-to-PUFA ratio that suppresses lipid reactive oxygen species (ROS) accumulation, protecting PDAC cells from iron-dependent lipid peroxidation and conferring ferroptosis resistance (PMID: 41049011).
Linoleic acid operates through a structurally distinct mechanism. As an omega-6 PUFA with two bis-allylic hydrogen atoms susceptible to radical abstraction, exogenous linoleic acid increases the pool of oxidisable membrane phospholipids. In MIA-PaCa2 and Suit-2 PDAC cell lines, linoleic acid treatment directly elevates lipid peroxidation, triggering ferroptotic cell death accompanied by phosphorylation of RIP3 and MLKL, the effectors of necroptotic membrane rupture (PMID: 38388563). This death cascade is specifically reversed by ferrostatin-1 (a lipid peroxidation inhibitor), confirming that the primary insult is ferroptotic rather than classical necroptotic (PMID: 38388563). However, at lower concentrations and in the context of chronic dietary omega-6 enrichment, linoleic acid increases PIP3 (phosphatidylinositol 3,4,5-trisphosphate) at the plasma membrane by altering the PIP2-to-PIP3 ratio, enhancing AKT recruitment and phosphorylation (PMID: 39796583). Omega-6 fatty acids also promote phosphorylation of the pro-apoptotic regulators FOXO3a and BAD, inhibiting apoptosis and supporting survival (PMID: 39796583). This dose-dependent and context-dependent duality distinguishes linoleic acid from oleic acid: at acute high doses it kills through ferroptosis; at chronic physiological levels it may promote tumour growth through AKT.
Cellular and molecular damage from lipid metabolic reprogramming in PDAC
At the cellular level, oleic acid drives the expansion of CD133+ pancreatic cancer stem cells (PaCSCs). Oleic acid supplementation enhances sphere formation, colony formation, and in vivo tumorigenicity of PaCSCs, while linoleic acid shows no significant effect on PaCSC functionality in the same experimental models (PMID: 39198858). PaCSCs rely on mitochondrial oxidative phosphorylation and FAO for bioenergetic maintenance; inhibition of FAO with ranolazine reduces CD133+ populations and sensitises patient-derived xenograft models to gemcitabine (PMID: 39198858). Under acidic microenvironment conditions (a hallmark of the PDAC tumour compartment), PDAC cells shift their metabolic dependency from glycolysis to FAO using scavenged lipids, and this shift is specifically required for low-pH-induced invasive behaviour (PMID: 32081432).
The chemoresistance programme converges on SCD1. In GelMA hydrogel models mimicking stiff PDAC stroma, SCD1 inhibition with CAY10566 sensitises cells to gemcitabine, while exogenous oleic acid rescues this resistance (PMID: 40741620). FASN (fatty acid synthase), ACLY (ATP citrate lyase), and ACC (acetyl-CoA carboxylase) are concurrently upregulated under stiff matrix conditions, increasing triglyceride content and lipid droplet accumulation (PMID: 40741620). The PDGFC-SREBP1 axis further compounds this damage at the metastatic level: aberrant PDGFC expression drives lipid accumulation through SREBP1, facilitating liver metastasis in vivo; the SREBP1 inhibitor betulin attenuates both proliferation and metastasis (PMID: 39225567). Linoleic acid, when applied at ferroptosis-inducing concentrations, inflicts oxidative damage on membrane phospholipids, but its ability to suppress gemcitabine-resistant PDAC cells is delayed compared to sensitive lines, indicating that resistant populations retain partial ferroptosis evasion mechanisms (PMID: 38388563).
Downstream pathophysiological outcome: a lipid-driven self-amplifying resistance circuit in PDAC
The oleic acid programme establishes a self-amplifying circuit in which desmoplastic stiffness activates Piezo1, Piezo1 triggers PI3K-AKT, AKT upregulates SREBP1-SCD1, SCD1 produces oleic acid, and oleic acid raises the MUFA-to-PUFA ratio to suppress ferroptosis while fuelling PaCSC self-renewal and FAO-dependent bioenergetics. Nutrient deprivation reinforces this loop by activating mTOR-SREBP1-SCD1 independently of mechanical input (PMID: 41049011). Linoleic acid can break this circuit at the ferroptosis node, but only at supraphysiological concentrations; at dietary levels, it paradoxically feeds AKT activation through PIP3 enrichment (PMID: 39796583). The most promising pharmacological intervention points are mTOR inhibition (rapamycin reverses SREBP1-SCD1 upregulation and restores ferroptosis sensitivity), SCD1 inhibition (CAY10566 disrupts MUFA supply), and FAO inhibition (ranolazine collapses PaCSC bioenergetics), each targeting a distinct node of the same feed-forward metabolic loop (PMID: 41049011; PMID: 40741620; PMID: 39198858).
Frequently asked questions
How does oleic acid promote pancreatic cancer progression?
Oleic acid enhances the self-renewal capacity of pancreatic cancer stem cells (CD133+), activates PI3K-AKT-mTOR signaling, and increases the intracellular MUFA-to-PUFA ratio, which suppresses lipid peroxidation and confers resistance to ferroptosis. It is the primary product of the SREBP1-SCD1 axis, which is upregulated under nutrient deprivation and stiff matrix conditions.
How does linoleic acid suppress pancreatic cancer growth?
Linoleic acid, as a polyunsaturated fatty acid, is susceptible to iron-dependent oxidation. Exogenous linoleic acid increases lipid peroxidation in PDAC cell lines, triggering ferroptosis. This is accompanied by phosphorylation of RIP3 and MLKL, inducing a necroptotic cell death programme that is reversed by the ferroptosis inhibitor ferrostatin-1.
What is the SREBP1-SCD1 axis and why does it matter in PDAC?
SREBP1 is a transcription factor that drives lipid biosynthesis. SCD1 (stearoyl-CoA desaturase 1) is the enzyme it activates to convert saturated fatty acids into monounsaturated fatty acids, primarily oleic acid. In PDAC, the SREBP1-SCD1 axis is upregulated under nutrient deprivation and mechanical stiffness, conferring chemoresistance and ferroptosis resistance.
What role does matrix stiffness play in PDAC lipid metabolism?
Stiff extracellular matrix activates the mechanosensitive ion channel Piezo1, which triggers calcium influx and downstream PI3K-AKT signaling. This upregulates SCD1 expression, increasing monounsaturated fatty acid synthesis and conferring chemoresistance to gemcitabine in PDAC cells.
Can targeting fatty acid oxidation improve PDAC treatment?
Pancreatic cancer stem cells depend on mitochondrial fatty acid oxidation for survival. Inhibiting FAO with ranolazine reduces CD133+ cancer stem cell populations and sensitises patient-derived xenograft models to gemcitabine. Under acidic microenvironment conditions, PDAC cells shift from glycolysis to FAO, making this pathway a viable adjunct therapeutic target.
Does dietary fatty acid composition influence pancreatic cancer risk?
Epidemiological data suggest that increased PUFA consumption correlates with PDAC incidence, particularly when omega-6 intake rises disproportionately relative to omega-3. Omega-6 fatty acids like linoleic acid can increase PIP3 levels at the plasma membrane, enhancing AKT recruitment and tumour proliferation. However, acute high-dose linoleic acid can also suppress growth via ferroptosis, creating a dose-dependent and context-dependent paradox.
What therapeutic combinations target the SREBP1-SCD1 axis in PDAC?
Rapamycin (mTOR inhibitor) reverses nutrient-deprivation-induced SREBP1 and SCD1 upregulation and restores ferroptosis sensitivity. The combination of sorafenib (a ferroptosis inducer) and rapamycin has shown synergistic antitumour effects. SCD1 inhibition with CAY10566 sensitises PDAC cells to chemotherapy, and FASN inhibition with C75 reduces gemcitabine resistance.
Map lipid signaling cascades in pancreatic cancer with PubMed-verified evidence
BioSkepsis traces every molecular claim to a verified PMID. Run your own pathway analysis on SREBP1-SCD1, ferroptosis regulators, or any lipid metabolism target in PDAC.
Start freeSources and further reading
- Mascaraque M, Courtois S, Royo-Garcia A, et al. Fatty acid oxidation is critical for the tumorigenic potential and chemoresistance of pancreatic cancer stem cells. J Transl Med. 2024;22(1):797. PMID: 39198858. DOI
- Zhang Z, Cai X, Gong Y, et al. SREBP1-SCD1 enhanced MUFAs biosynthesis drives nutrient deprived pancreatic cancer cell ferroptosis resistance. J Cancer. 2025;16(13):3960-3971. PMID: 41049011. DOI
- Zhang X, Zhu B, Yan J, et al. Matrix stiffness boosts PDAC chemoresistance via SCD1-dependent lipid metabolic reprogramming. Regen Biomater. 2025;12:rbaf056. PMID: 40741620. DOI
- Torres C, Mancinelli G, Chen JE, et al. Cell membrane fatty acids and PIPs modulate the etiology of pancreatic cancer by regulating AKT. Nutrients. 2024;17(1):150. PMID: 39796583. DOI
- Suda A, Umaru BA, Yamamoto Y, et al. Polyunsaturated fatty acids-induced ferroptosis suppresses pancreatic cancer growth. Sci Rep. 2024;14(1):4409. PMID: 38388563. DOI
- Shi YH, Liu ZD, Ma MJ, et al. Platelet-derived growth factor C facilitates malignant behavior of pancreatic ductal adenocarcinoma by regulating SREBP1 mediated lipid metabolism. Adv Sci (Weinh). 2024;11(40):e2407069. PMID: 39225567. DOI
- Shin SC, Thomas D, Radhakrishnan P, Hollingsworth MA. Invasive phenotype induced by low extracellular pH requires mitochondria dependent metabolic flexibility. Biochem Biophys Res Commun. 2020. PMID: 32081432. DOI